These findings are consistent with imatinib’s multi-kinase inhibition profile, particularly against PDGFR, c-KIT, and ABL kinases, and suggest broad repositioning opportunities across CNS, cardiovascular, metabolic, and autoimmune conditions. This evidence concerns the gene KIT and Autoimmunity.